The Filing Desk

Bausch & Lomb

BLCO · NYSE · Health Care · Financials, fiscal 2020 to 2025

BLCO · Last close · November 19, 2026
$20.69
Value Bausch & Lomb yourself

Bausch & Lomb's revenue rose 6.5% to $5.1 billion in fiscal 2025. Its operating margin was 2.2%, down from 3.4% a year earlier. Free cash flow was −$66 million. The diluted share count rose 0.6%.

Bausch & Lomb Corp Latest fiscal year ended December 31, 2025 10-K filed February 18, 2026 · 0001860742-26-000007 Updated
Revenue
$5.1B
6.5%
Operating margin
2.2%
1.2 pts
Net income
−$360M
 
Free cash flow
−$66M
 
Return on capital
0.8%
0.3 pts
Market cap
$7.5B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Bausch & Lomb does

Bausch + Lomb sells products for eye health in about 100 countries. Its portfolio of about 400 products includes contact lenses, lens care products, intraocular lenses (artificial lenses implanted in the eye), surgical systems and devices, prescription eye medicines, vitamins and mineral supplements, and other consumer products. It has about 13,000 employees.

It sells to consumers through stores and online, and to eye doctors, surgeons and hospitals. It says its range covers nearly all areas of the eye health market, and it competes with other eye health and medical device companies in each of them.

The company was founded in 1853 and is a subsidiary of Bausch Health Companies (BHC), which holds about 88% of its shares. Its shares began trading on the NYSE and the Toronto Stock Exchange in May 2022. BHC has said it still wants to separate the two companies, by selling its stake, selling Bausch + Lomb or giving the shares to its own shareholders, but there is no assurance that this will happen.

Its biggest risks, as it describes them

  • BHC's separation plan may not be completed or may not bring the expected benefits.
  • BHC controls the direction of the business until the separation is complete.
  • Product liability claims if its products are said to have caused harm.
  • Impairment of its large goodwill and other intangible assets, which could hurt profits.
  • Legal and government proceedings that are costly and uncertain.
From Bausch & Lomb's annual report on Form 10-K, filed February 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2021 to 2022, earnings per share fell 96.2% a year and net income 96.7% a year, with the share count about the same. Bausch & Lomb then lost money in fiscal 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments174354331305383
Debt incl. finance leases02,4364,5624,7845,048
Net debt (negative means net cash)−1742,0824,2314,4794,665
Net debt to EBITDA−0.2x3.5x8.3x7.5x8.7x
Debt to equity0.0x0.3x0.7x0.7x0.8x
Interest coverage—1.4x0.5x0.4x0.3x
Current ratio1.5x1.6x1.7x1.6x1.6x
Quick ratio1.0x1.2x1.1x1.0x1.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Bausch & Lomb's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 9 insiders bought $1.2 million of Bausch & Lomb shares on the open market, and 2 insiders sold $1.2 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 10, 2026Frederick MunschSVP, Controller and CAOSold52,900$16.78$887,662Form 4
Aug 7, 2026Eschenbach Andrew C. VonDirectorSold6,059$16.58$100,458Form 4
Aug 6, 2026Eschenbach Andrew C. VonDirectorSold12,500$16.50$206,250Form 4
Mar 6, 2026Brent L SaundersCEO and Chairman of the Board, DirectorBought14,700$17.14$251,958Form 4
Mar 6, 2026A Robert D BaileyEVP & Chief Legal OfficerBought14,600$17.15$250,390Form 4
Mar 6, 2026Sam EldessoukyEVP and CFOBought4,000$17.13$68,520Form 4
Mar 3, 2026Thomas W. Ross Sr.DirectorBought4,500$17.68$79,560Form 4
Mar 2, 2026Eduardo AlfonsoDirectorBought4,300$17.90$76,970Form 4
Feb 27, 2026Eschenbach Andrew C. VonDirectorBought4,364$18.31$79,905Form 4
Feb 23, 2026Steven H CollisDirectorBought15,000$17.81$267,150Form 4
Feb 20, 2026Russel C RobertsonDirectorBought4,400$17.90$78,760Form 4
Feb 19, 2026Karen LingDirectorBought4,000$17.74$70,960Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 83 of 83 of 8
Rule of 405.3%14.3%5.2%
Altman Z''1.691.451.24
Accruals ratio−2.0%−4.1%−4.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score3 of 83 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Bausch & Lomb side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Bausch & LombFY256.5%2.2%−1.3%0.8%8.7x3
Cooper CompaniesFY255.1%16.7%10.6%4.3%2.3x5Compare
Align TechnologyFY250.9%13.5%12.2%13.3%−1.4x5Compare
Dentsply SironaFY25−3.0%−11.5%2.8%−9.9%—6Compare
West Pharmaceutical ServicesFY256.2%19.0%15.2%18.7%−0.8x9Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue3,4123,7653,7684,1464,7915,101
Revenue growth—10.3%0.1%10.0%15.6%6.5%
Gross profit——————
Research and development253271307324343371
Operating income260329207130162113
Net income−181826−260−317−360
Diluted EPS (US$)−0.050.520.02−0.74−0.90−1.02
Diluted shares (millions)350350350350352354
Cash flow
Cash from operations522873345−17232283
Capital expenditure253193175181291349
Free cash flow269680170−198−59−66
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation5062627492149
Balance sheet at fiscal year end
Cash and short-term investments238174354331305383
Debt incl. finance leases—02,4364,5624,7845,048
Total assets—10,82311,14413,44213,46914,022
Total liabilities—1,4214,0436,5226,9257,503
Shareholders' equity9,9889,3297,0336,8506,4736,448
Margins and ratios
Gross margin——————
Operating margin7.6%8.7%5.5%3.1%3.4%2.2%
Net margin−0.5%4.8%0.2%−6.3%−6.6%−7.1%
Free cash flow margin7.9%18.1%4.5%−4.8%−1.2%−1.3%
Rule of 40 (growth + FCF margin)—28.4%4.6%5.3%14.3%5.2%
Return on capital——1.1%1.0%1.1%0.8%
Return on equity——0.1%−3.8%−4.8%−5.6%
Return on assets——0.1%−2.1%−2.4%−2.6%
Net debt to EBITDA—−0.2x3.5x8.3x7.5x8.7x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Bausch & Lomb's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Bausch & Lomb.